Patents Assigned to Eye Therapies LLC
-
Patent number: 11833245Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: January 30, 2023Date of Patent: December 5, 2023Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Patent number: 11717478Abstract: The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.Type: GrantFiled: May 12, 2021Date of Patent: August 8, 2023Assignee: EYE THERAPIES LLCInventor: Gerald Horn
-
Patent number: 11596600Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: January 26, 2022Date of Patent: March 7, 2023Assignee: Eye Therapies, LLCInventor: Gerald Horn
-
Patent number: 11026884Abstract: The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.Type: GrantFiled: January 22, 2019Date of Patent: June 8, 2021Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Patent number: 9259425Abstract: The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: GrantFiled: October 3, 2013Date of Patent: February 16, 2016Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Patent number: 8987270Abstract: The invention provides compositions and methods utilizing low concentrations of selective ?-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective ?-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective ?-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness.Type: GrantFiled: September 7, 2012Date of Patent: March 24, 2015Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Patent number: 8952011Abstract: The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: GrantFiled: August 26, 2013Date of Patent: February 10, 2015Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Patent number: 8765758Abstract: The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: GrantFiled: December 17, 2010Date of Patent: July 1, 2014Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Publication number: 20140038974Abstract: The invention provides compositions and methods for whitening of eyes and/or reducing redness of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine, dexmedetomidine, guanfacine or fadolmidine.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: Eye Therapies, LLCInventor: Gerald Horn
-
Publication number: 20140038973Abstract: The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: Eye Therapies, LLCInventor: Gerald Horn
-
Publication number: 20130345229Abstract: The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: ApplicationFiled: August 26, 2013Publication date: December 26, 2013Applicant: Eye Therapies, LLCInventor: Gerald Horn
-
Patent number: 8580787Abstract: The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: July 27, 2009Date of Patent: November 12, 2013Assignee: Eye Therapies LLCInventor: Gerald Horn
-
Publication number: 20130172357Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: February 5, 2013Publication date: July 4, 2013Applicant: EYE THERAPIES LLCInventor: Eye Therapies LLC
-
Publication number: 20130143938Abstract: Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists.Type: ApplicationFiled: February 1, 2013Publication date: June 6, 2013Applicant: Eye Therapies LLCInventor: Eye Therapies LLC